Nervonik has successfully concluded its inaugural human clinical trial involving their peripheral nerve stimulation (PNS) device. Based in Los Angeles, the innovative startup has engineered a unique device aimed at improving therapeutic outcomes for chronic pain management. This technology utilizes precisely controlled electrical currents to engage peripheral nerves, altering pain transmission to alleviate discomfort.
Developed in the UCLA laboratory of Dr. Aydin Babakhani, who also founded Nervonik, the technology has taken a significant leap forward with this study. “This clinical trial signifies a major advancement for Nervonik, allowing us to evaluate our novel approach to chronic pain treatment,” stated Babakhani, highlighting the collaborative effort in system development and clinical application involving top-tier medical professionals and researchers.
Conducted at the Punta Pacifica Hospital in Panama City, Panama, an affiliate of Johns Hopkins, the study focused on individuals suffering from persistent shoulder or knee pain. Dr. Timothy Deer, the president and CEO of The Spine and Nerve Centers of the Virginias, led the surgical implantation of miniature leads, employing fluoroscopic and ultrasound guidance to precisely target various nerves.
The investigative team connected these leads to compact, implantable pulse generators (IPGs), powered by a small, programmable wearable device. The stimulation settings for each patient were personalized using a specialized app, ensuring maximum treatment efficiency.
Working as the principal investigator, Dr. Ricardo Bermudez from Punta Pacifica anticipates disclosing the study’s findings by early 2025. Jeff Kramer, Nervonik’s chief scientific officer, commented, “Our treatment strategy is grounded in a deeper understanding of how PNS interacts with the neurological underpinnings of chronic pain, which allows us to optimize patient experiences.”